Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHABLIS-SC1: Blisibimod in SLE
NCT01395745Phase 3Completed
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Feb 2013
- Primary completion
- Jul 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 16
01
Overview
A Phase 3 trial of blisibimod in systemic lupus erythematosus (SLE), sponsored by Anthera Pharmaceuticals, Inc.. Started Feb 2013; status: completed.
02
Drugs
blisibimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT01395745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01395745.